FINRA Files Settled Enforcement Action Involving Sales of Shares

Note: This article is for informational purposes only and is based on public regulatory materials and related legal analysis.

Some enforcement headlines sound like they were drafted by a robot wearing reading glasses. This one, however, deserves a human translation. When FINRA files or resolves a settled enforcement action involving sales of shares, it usually is not obsessing over paperwork for paperwork’s sake. It is looking at a bigger question: did a broker-dealer become part of an unlawful distribution, ignore obvious red flags, or treat anti-money laundering controls like optional office décor?

That is exactly why a settled FINRA matter involving the sale of company shares has drawn attention from compliance officers, broker-dealers, securities lawyers, and frankly anyone who has ever heard the phrase “low-priced stock” and immediately checked whether their wallet was still in their pocket. The case shows how share-sale activity can trigger a collision of Securities Act registration rules, FINRA supervision duties, and AML expectations all at once.

At the center of the story is a FINRA settlement with former registered representative and compliance officer Mark Bedros Beloyan. In October 2023, FINRA accepted a settlement under which Beloyan was assessed a deferred $60,000 fine, suspended for two years, and ordered to pay deferred disgorgement of commissions plus prejudgment interest. FINRA found that he facilitated the liquidation of nearly 23 million shares of common stock to the investing public when no registration statement was in effect and no exemption was available. The sales generated roughly $577,000 in proceeds, and FINRA said Beloyan was a necessary participant because he opened the accounts, approved the deposits, executed the sales, and handled supervision and compliance functions at the firm.

What the settled FINRA action was really about

On the surface, this was a case about sales of shares. Under the hood, it was a case about gatekeeping. FINRA concluded that Beloyan did not merely stand near the transaction with a clipboard and a worried expression. He was deeply involved in the mechanics of getting the shares into accounts and out to market.

According to FINRA’s findings, he failed to conduct adequate due diligence to determine whether the shares were registered or exempt from registration under Section 5 of the Securities Act. FINRA also found that he failed to investigate red flags suggesting the transactions were part of an unregistered distribution. That distinction matters. Enforcement in this area does not require a broker to be the issuer, the mastermind, or the person twirling a villain mustache in the background. Being a “necessary participant” or a “substantial factor” in the sale can be enough to create serious exposure.

FINRA’s findings went further. The regulator said Beloyan also failed to implement an AML program reasonably designed to detect and report suspicious activity, failed to evaluate whether suspicious activity reports should be filed, and misled a clearing firm about the involvement of an individual who had previously been sued by the SEC in unrelated penny-stock manipulation matters. In other words, the case was not just “Were these shares saleable?” It was also “Why did so many warning lights flash, and why did nobody hit the brakes?”

Why Section 5 keeps showing up like the strict teacher in the hallway

Section 5 of the Securities Act is one of those rules that sounds straightforward until a firm tries to apply it in the wild. In simple terms, offers and sales of securities generally must be registered unless an exemption applies. SEC guidance makes clear that a prima facie Section 5 violation can be established when there is no registration statement, a person sold or offered to sell the securities, and interstate means were used. Importantly, scienter is not required. That means “I didn’t mean to” is not the superhero cape some people think it is.

Broker-dealers often look to exemptions such as the Section 4(a)(4) broker’s transaction exemption. But the SEC has repeatedly stressed that a broker-dealer cannot rely on that exemption if it knows, or has reasonable grounds to believe, that the customer’s sale is not exempt from Section 5. The SEC also says the broker must conduct a reasonable inquiry before executing the sale. Translation: a firm cannot shrug, accept self-serving explanations, and hope the legal fairy handles the rest overnight.

That principle is not new. FINRA’s Regulatory Notice 09-05 reminded firms that they must take reasonable steps to ensure they do not become participants in unregistered distributions and that they may not simply rely on transfer agents, clearing firms, issuer counsel, or other third parties to do the hard thinking for them. The notice specifically warned about classic red flags: large blocks of thinly traded or low-priced securities, immediate sales followed by outgoing wires, recently issued certificates, shell-company histories, issuer name changes, and stale or missing SEC filings.

Why the “we thought it was exempt” defense often wilts on contact

FINRA and the SEC do not expect perfection, but they do expect inquiry. If a customer appears with a giant pile of low-priced shares, wants them sold fast, and cannot clearly explain where they came from, the correct reaction is not “Cool, let’s see what the market gives us.” It is “Stop, document, investigate, escalate.”

That is one reason this case resonates. FINRA found Beloyan approved deposits, handled the accounts, executed the sales, and still failed to do enough to determine whether the transactions were lawful. In enforcement-speak, that is the regulatory equivalent of being caught holding both the map and the steering wheel.

Red flags that made this settlement unsurprising

The case also fits neatly into FINRA’s broader guidance on suspicious activity in low-priced securities. Regulatory Notice 19-18 highlights patterns such as opening a new account, depositing a large block of thinly traded or low-priced shares, selling quickly, and wiring out the proceeds. Regulatory Notice 21-03 expands the warning list and makes clear that firms engaged in low-priced securities business can expect heavier scrutiny, more detailed reviews, and a sharper regulatory eye.

Once you line up those red flags next to FINRA’s findings in the Beloyan matter, the picture becomes uncomfortably crisp. Large share blocks? Check. Low-priced or penny-stock concerns? Check. Questions about relationships, beneficial ownership, and source of shares? Check. Suspicious nominee-account activity and clearing-firm inquiries? Also check. At that point, the compliance issue is not hidden in a footnote. It is standing in the lobby asking whether anyone has seen the AML manual lately.

This was not an isolated one-off

One of the biggest mistakes firms make after a settlement like this is treating it as a weird outlier tied to one bad actor. That is not how FINRA has approached the issue. The regulator has been hammering the same themes for years: reasonable inquiry, supervision, AML monitoring, documentation, and escalation.

Consider another 2023 FINRA settlement involving Maxim Group. FINRA fined the firm $500,000 and required it to retain an independent consultant after finding supervisory and AML deficiencies tied to transactions in DVP/RVP accounts and low-priced securities. FINRA said the firm lacked procedures specifically designed to address Section 5 compliance in that business line, relied on due diligence performed elsewhere, failed to obtain enough information about how customers acquired shares or their relationships to issuers, and did not reasonably investigate red flags in suspicious trading. That should sound very familiar, because regulators love patterns almost as much as compliance people love checklists.

Or look at the July 2023 Fried Frank summary of a FINRA settlement involving unregistered distributions in private placements. There, the issue was not penny stocks dumped into the market, but failure to satisfy the conditions of a claimed exemption in Regulation D sales. The point is the same: if a firm sells securities without establishing that an exemption really fits, Section 5 problems appear quickly and expensively.

And the theme goes back even further. A review of major 2015 FINRA enforcement actions highlighted a landmark case in which a firm was fined $6 million and ordered to disgorge $1.3 million in commissions for selling 73.6 billion shares of microcap securities without adequate due diligence. That older matter remains important because it shows the regulator’s long-standing view: high-risk share-sale business requires tailored supervision, real controls, and staff who know a red flag when it smacks them in the face.

Why AML and share-sales enforcement now travel as a package deal

Modern FINRA cases involving sales of shares rarely stay inside one neat legal box. That is because suspicious share sales often raise both registration concerns and AML concerns at the same time. If a firm is dealing with low-priced securities, fast liquidations, nominee accounts, unusual wires, or customers with questionable ties to issuers, the firm is now living in a neighborhood patrolled by both Section 5 and AML expectations.

FINRA has made this crystal clear. In 2022, it updated its Sanction Guidelines to add specific AML guidelines and emphasized that AML compliance is a regulatory priority. Outside analyses also show the theme continuing. Eversheds Sutherland’s 2025 FINRA sanctions study reported that AML was the top enforcement category by total fines in 2025, even as overall disciplinary actions declined. InvestmentNews and other trade coverage echoed that the case count fell, but major sanctions in AML and related control failures still mattered. So yes, fewer total cases may sound comforting, but for firms in risky product or microcap lanes, that is not exactly a permission slip to nap through surveillance alerts.

Holland & Knight’s discussion of 2023 SEC and FINRA settlements involving broker-dealers reinforced the same lesson: firms that mishandle suspicious activity, short-sale controls, or microcap order flow can face large penalties even when they later self-report and remediate. Regulators may give credit for cleanup, but they still send the bill.

What broker-dealers should learn from this case right now

1. Know the source of the shares

That means knowing how the customer acquired the securities, when they were acquired, whether the seller is affiliated with the issuer, whether the securities are restricted or control securities, and whether any claimed exemption actually works under the facts. A memo with vague assurances is not a due diligence program.

2. Stop outsourcing your brain

FINRA has said firms cannot rely solely on clearing firms, transfer agents, or issuer counsel to satisfy their obligations. Third parties may help, but the member firm keeps the legal and supervisory responsibility. The regulator’s position is essentially: outsource a function if you want, but do not outsource your pulse.

3. Build procedures around the actual business line

FINRA Rule 3110 requires supervisory systems and written procedures reasonably designed for the business a firm actually conducts. If a firm handles low-priced securities, private placements, DVP/RVP accounts, or heavy share-liquidation activity, its procedures have to address those risks specifically. Boilerplate manuals that read like they were copied from a generic compliance starter pack will not help much when examiners ask hard questions.

4. Treat red flags as escalation triggers, not background noise

New accounts, large blocks, quick sales, nominee structures, related parties, inconsistent explanations, frequent outgoing wires, shell-company histories, and stale issuer disclosures should all trigger review. If the firm’s culture turns every alert into “close and move on,” the next thing to close may be someone’s career options.

5. Document the inquiry like you expect to explain it later

Because you probably will. Good files should show what was reviewed, who reviewed it, what questions were asked, what answers were received, what inconsistencies were noticed, and why the firm concluded the transaction could proceed. A good outcome with poor documentation is still a bad exam day.

6. Make AML surveillance fit the transaction risk

Low-priced securities and suspicious liquidations need surveillance tailored to those patterns. Alerts should be reviewed promptly, closed with analysis, and escalated when facts support possible SAR filing. A queue full of ignored alerts is not a workflow; it is a future exhibit.

Why investors and issuers should care too

This type of case is not just a compliance seminar with more acronyms. For investors, unlawful distributions and poorly supervised share sales can distort prices, hide manipulative activity, and create markets filled with information fog. For legitimate issuers, it can mean reputational damage by association if their shares appear in suspicious resale patterns. For firms, it can mean fines, suspensions, disgorgement, consulting undertakings, remediation costs, and the kind of internal review that makes everyone suddenly wish they had replied to compliance emails faster.

It also matters because enforcement in this area sends a message about role responsibility. FINRA is telling the market that selling shares is not a purely mechanical act when the facts suggest something more serious. If a representative or principal opens the accounts, approves the deposits, knows the players, and pushes the trades through anyway, the regulator may view that person as part of the distribution itself.

Experience from the trenches: what these share-sale cases usually feel like inside a firm

In real-world terms, matters like this rarely begin with cinematic drama. They usually begin with something painfully ordinary: a deposit review ticket, a clearing-firm question, an alert in the AML queue, a legal memo that feels a little too thin, or an operations employee who says, “This looks odd, but I’m not sure why.” Then the case grows teeth.

People who have worked around these issues often describe the same pattern. First comes the rush to understand the customer story. Where did the shares come from? Why this issuer? Why this timing? Why are the shares being sold now? Why is the customer in such a hurry? Why does the explanation get fuzzier every time someone asks a follow-up? That is usually the moment when a firm learns whether it has a real escalation culture or just a motivational poster about escalation hanging near the copier.

Next comes the paperwork scramble. Compliance wants account-opening files, stock powers, legal opinions, issuer records, communications, prior deposits, wire activity, surveillance notes, and every piece of documentation showing who approved what and when. Operations wants to know whether the shares can settle. Supervisors want to know whether someone else already approved the transaction. Legal wants everyone to stop using casual phrases in emails. And somewhere in the middle of this chaos, a registered representative is still insisting the customer is “totally legitimate” because they once had lunch together and the customer seemed nice.

Then the emotional temperature rises. If a clearing firm asks direct questions, people inside the introducing firm suddenly understand that this is no longer a routine processing matter. Clearing-firm inquiries can be the regulatory equivalent of hearing thunder before the storm hits. They often reveal weak spots fast: missing source-of-shares information, vague beneficial-owner explanations, undocumented conclusions, or supervisors who approved a sale without being able to explain the exemption analysis in plain English.

What experienced compliance teams learn is that these cases are rarely defeated by cleverness. They are usually prevented by habits. Good firms slow down when a transaction is moving too fast. They ask the second and third question. They verify instead of assuming. They train staff on specific red flags rather than generic “be careful” slogans. They document the rationale for approving or rejecting the sale. They understand that low-priced share activity is not merely a trading issue; it is a source-of-securities issue, a supervision issue, and often an AML issue too.

Another common experience is the painful realization that a firm’s written procedures looked fine until someone tried to use them. On paper, the firm may have had policies about red flags, escalation, and suspicious activity. In practice, those policies may have been too broad, too old, too generic, or too disconnected from the actual business line. That gap between “the manual says” and “the desk does” is where a lot of enforcement cases are born.

The firms that come out of these episodes in one piece usually do three things well. They respond quickly, they preserve records, and they fix root causes rather than cosmetic symptoms. They do not just add another form and call it a day. They redesign approvals, surveillance, training, and ownership of the process. That is the unglamorous truth of securities compliance: sometimes the hero of the story is not the rainmaker. It is the person who refused to approve the sale until the facts made sense.

Conclusion

The settled FINRA action involving sales of shares is a reminder that in securities regulation, the “sale” is never just the sale. It is the due diligence before the trade, the supervision around the trade, the AML review behind the trade, and the documentation that explains why the trade should have happened at all.

The Beloyan settlement, together with FINRA’s long-running guidance and similar enforcement actions, shows a very consistent regulatory view: when firms or associated persons handle suspicious share liquidations without performing a real inquiry, they risk becoming participants in unlawful distributions and creating AML failures at the same time. For firms that operate anywhere near low-priced securities, private placements, or concentrated share deposits, the lesson is not subtle. Ask more questions, escalate faster, document better, and never assume that someone else checked the hard stuff. In this corner of the market, “probably fine” is not a compliance strategy. It is a future headline.